Amifostine antioxidant effect on serum of rats treated with cyclophosphodamide

Polish Journal of Environmental Studies

Volumn 14, Issue 3, 2005, Pages 341-346

  Stankiewicz, A ^a   Skrzydlewska, E ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Amifostine; Antioxidative ability; Blood serum; Cyclophosphamide; Lipid peroxidation

Indexed keywords

EID: 18544388219     PISSN: 12301485     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. BONADONNA G., VALAGUSSA P., MOLITERNI A. ZAMBETTI M., BRAMBILLA C., Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer, N. Engl. J. Med., 332, 901, 1995
2. MURPHY S. B., BOWMAN W. P., COOPER M. J., Results of treatment of advanced stage Burkitts lymphomas and B-cell (Sig+) acute lymphoblastic leukaemia with high dose fractionated cyclophosphamide and co-ordinated high-dose methotrexate and cytarabine, J. Clin. Oncol., 4, 1732, 1986
3. REITER A., ACHRAPPE M., LUDWIG W. D., HIDDEMANN W., SAUTER S., HENZE G., ZIMMERMANN M., LAMPERT F., HAVERS W., NIETHAMMER D., Chemotherapy in 998 unselected childhood acute lymphoblastic leucemia patients. Results and conclusions of the multicenter trial ALL-BFM 86, Blood, 84, 3122, 1994
4. CAPIZZI R. L., Amifostine: the preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies, Semin. Oncol., 23, 2, 1996
5. PARKE D. V., SAPOTA A., Chemical toxicity and reactive oxygen species, Int. J. Occup. Med. Env. Health., 9, 331, 1996
6. SCHLEZINGER J., WHITE R. D., STEGEMAN J., Oxidative inactivation of cytochrome P450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1, As. Mol. Pharmacol., 56, 588, 1999
7. KANEKAL S., KEHRER J. P., Metabolism of cyclophosphamide by lipooxygenases, Drug Metab. Disposition, 22, 74, 1994
8. KANEKAL S., KEHRER J., Evidence for peroxidase-mediated metabolism of cyclophosphamide, Drug Metab. Disposition., 21, 37, 1993
9. FRAISER L., KANEKAL S., KEHRER J. P., Cyclophosphamide toxicity: characterizing and avoiding the problem, Drugs, 42, 781, 1991
10. LEVINE L. A., RICHIE J. P., Urological complications of cyclophosphamide. J. Urol. 141, 1063, 1989
11. STANKIEWICZ A., SKRZYDLEWSKA E., Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms, Toxicol. Mech. Methods., 13, 1, 2003
12. CZEJKA M., SCHUELLER J., EDER I., REZNICEK G., KRAULE C., ZELENI U., FREITAG R., Clinical pharmacocinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine, Anticancer Res., 20, 3871, 2000
13. DORR R T., Cytoprotective agents for antracyclines, Semin. Oncol., 23 , 23, 1996
14. VAN der VIJGH W. J. F., KORST A. E. C., Amifostine (Ethyol): pharmacocinetic and pharmacodynamic effects in vivo, Eur. J. Cancer, 32, 26, 1996
15. MISRA H. P., FRIDOVICH I., The role of superoxide anion in the autooxidation of epinefrine and a simple assay for superoxide dismutation, J. Biol. Chem., 247, 3170, 1972
16. SYKES J. A., McCORMAC F. X., O'BREIEN T. J., Preliminary study of the superoxide dismutase content of some human tumors, Cancer Res., 38 , 2759, 1978
17. PAGLIA D. E., VALENTINE W. N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med., 70, 158, 1967
18. MIZE C. E., LANGDON R. G., Hepatic glutathione reductase. I. Purification and general kinetic properties, J. Biol. Chem., 237, 1589, 1962
19. TAKESHITA S., NAKATA R., TSUKAMOTO I., Change in the level vitamin C and lipid peroxidation in tissues of the inherently scorbutic rat during ascorbate deficiency, J. Argic. Food Chem., 44, 2748, 1996
20. DELEENHERT A., DEBEVERE V., DERUTYER M. G., CLAEYS A. C. Simultaneus determination of retinol and α-tokoferol in human serum by HPLC, J. Chromatogr., 162, 408, 1979
21. YOSHINO K., MATSURA T., SANO M. Fluorometric lipid chromatographic determination of aliphatic aldehydes arising from lipid peroxides, Chem. Pharm. Bull., 34, 1694, 1986
22. LONDERO D., GRECO P. L., Automated HPLC separation with spectrofluorometric detection of malondialdehyde-thiobarbituric acid adduct in plasma, J. Chromatogr. A., 729, 207, 1996
23. MYERS C. E., Anthrocyclines. ed.; Pharmacologic Principles of Cancer Treatment: Philadelphia, pp 416-434, 1982
24. REED E., OZOLS R. F., TARONE R., Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. USA, 84, 5024, 1987
25. MATES J. M, PEREZ-GOMEZ C., NUNEZ de CASTRO. I., Antioxidant enzymes and human diseases, Clin. Biochem., 32, 595, 1999
26. BEERY C., ANDERSON N., KIRK A. J., DOMINICZAK A. F., McMURRAYAND J. J., Renin angiotensin system inhibition is associated with reduced free radical concentration in arteries of patients with coronary heart disease, Heart, 86, 217, 2001
27. SIEMS W., QUAST S., CARLUCCIO F., WISWEDEL I., HIRSCH D., AUGUSTIN W., HAMPL H., RIEHLE M., SOMMERBURG O., Oxidative stress in chronic renal failure as a cardiovascular risk factor, Clin. Nephrol., 58, S12, 2002
28. DURKEN M., AGBENU J., FINCKH B., HUBNER C., PICHLMEIER U., ZELLER W., WINKLER K., ZANDER A., KOHLSCHUTTER A., Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation, Bonne Marrow Transplant., 15, 7570, 1995
29. FRIDOVICH I., FREEMAN B., Antioxidant defenses in the lung, Ann. Rev. Physiol., 48, 693, 1986
30. GILBERT H., Redox control of enzyme activities by thiol/disulfide exchange, Method Enzymol., 107, 330, 1984
31. UCHIDA K., KANEMATSU M., SAKAI K., MATSUDA T., HATTORI N., MIZUNO Y., SUZUKI D., MIYATA T., NOGUCHI N., NIKI E., OSAWA T., Protein-bound acrolein: potential markers for oxidative stress, Proc. Natl. Acad. Sci., 95, 4882, 1998
32. RAMU K., FRAISER L. H., MAMIYA B., Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide, Chem. Res. Toxicol., 8, 515, 1995
33. HAENEN G.R., VERMEULEN N. P., TAI TIN TSOI J. N., RAGETI H.M., TIMMERMAN H., BLAST A., Activation of the microsomal glutathione S transferase and reduction of the glutathione dependent protection against lipid peroxidation by acrolein, Biochem. Pharmacol., 37, 1933, 1998
34. BURTON G. W., INGOID K. U., Vitamin E as an in vitro and in vivo antioxidant, Ann. NY Acad. Sci., 570, 72, 1989
35. CHOW C. K., Vitamin E and oxidative stress, Free Radic. Biol. Med. 11 , 215, 1991
36. LEE I. M., Antioxidant vitamins in prevention of cancer, Proc. Assoc. Am. Physicians., 111, 1, 1999
37. BRIZEL D. M., Future directions in toxicity prevention, Semin. Radiat. Oncol., 8, 17, 1998
38. LEWIS C., A review of the use of chemoprotectants in cancer chemotherapy, Drug Safety, 11, 153, 1994
39. SCHUCHTER L. M, Current role of protective agents in cancer treatment, Oncology, 11, 505, 1997
40. DOUAY L., HU C., GIARRATANA M. C., Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants, Semin. Oncol., 21, 16, 1994
41. FRIEDMAN H. S., COLVIN O. M., AISAKA K., POPP J., BOSSEN E. H., REIMER K. A., POMELL J. B., HILTON J., GROSS S. S., LEVI R., Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity, Cancer Res., 50, 2455, 1990
42. VENKATESAN N., CHANDRAKASAN G., Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant, Mol. Cell Biol., 142, 79, 1995
43. GRDINA D. J., KATAOKA Y., MURLEY J. S., Amifostine: mechanisms of action underlying cytoprotection and chemoprevention, Drug Metab. Drug Interact., 16, 237, 2000
44. MARZATICO F., PORTA C., MORONI M., BERTORELLI L., BORASIO E., FINOTTI N., PANSARASA O., CASTAGNA L., In vitro antioxidant properties of amifostine (WR-2721, Ethol), Cancer Chemother. Pharmacol., 45, 172, 2000
45. OHNISHI S. T., OHNISHI T., GLICK J. H., SCHEIN P. S., In vitro study on the antioxidant activities of amifostine (WR-2721), Proc. Am. Assoc. Cancer Res., 33, 419a, 1992
46. ORDITURA M., DeVITA F., ROSCIGNO A., Amifostine: a selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity, Oncol. Rep., 6, 1357, 1999
47. SHAW L. M., BONNER H. S., SCHUCHTER L., SCHILLER J., LIEBERMAN R., Pharmacokinetics of amifostine: effects of dose and method of administration, Semin. Oncol., 26, 34, 1999
48. SHAW L. M., BONNER H. S., BROWN D. Q., Metabolic pathways of WR-2721 (ethol, amifostine) in the BALB/c mause, Drug Metab. Dispos., 22, 895, 1994
49. STANKIEWICZ A., SKRZYDLEWSKA E., MAKIEŁA M., Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats, Drug Metab. Drug Interact., 19, 67, 2002
50. STANKIEWICZ A., SKRZYDLEWSKA E., SULKOWSKA M., SULKOWSKI S., Effect of amifostine on lung oxidative stress after cyclophosphamide therapy, Bull. Vet. Pulawy, 46, 87, 2002